4/13/2012

Abiomed has earned CE Mark approval to market its Impella cVAD system in Europe. The device, which has not yet obtained marketing clearance in the U.S., is designed to provide the heart’s left ventricle with temporary circulatory support without the need for surgery.

Related Summaries